Phillipp Ivanyi

13PUBLICATIONS
82CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 09, 2026
Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma.

|Jul 15, 2026
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.

|Nov 21, 2025
A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025-Standard and Considerations for an Individualized Treatment.

Philipp Ivanyi, Tabea Fröhlich, Jonas Paul Wiegmann

|Jul 29, 2025
Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial).

Johanna Falkenhorst, Philipp Ivanyi, Tom Schulz

|Dec 02, 2024
Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling.

Wenji Piao, Long Wu, Yanbao Xiong

|Apr 24, 2024
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz

Pageof 3

Frequent Collaborators

4 joint publications

Viktor Grünwald

2 joint publications

Hendrik Heers

2 joint publications

Sebastian Bauer

2 joint publications

Bernd Kasper